Sumitomo Pharma CoTSE:4506 -1.80%57 Days Payable is 81.71 as of Mar. 2026, which is 50% below its 10-year median of 162.50. GuruFocus rates TSE:4506 with a GF Score™ of 57/100 and a GF Value™ of 円832.67 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Sumitomo Pharma Co ranks worse than 57.48% on this metric.
The historical rank and industry rank for Sumitomo Pharma Co's Days Payable or its related term are showing as below:
TSE:4506'
s Days Payable Range Over the Past 10 Years
Min: 78.69 Med: 162.5 Max: 175.36
Current: 78.69
During the past 13 years, Sumitomo Pharma Co's highest Days Payable was 175.36. The lowest was 78.69. And the median was 162.50.
TSE:4506's Days Payable is ranked worse than 57.48% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs TSE:4506: 78.69
Sumitomo Pharma Co's Days Payable
declined
from Mar. 2025 (101.00) to Mar. 2026 (81.71).
It may suggest that Sumitomo Pharma Coaccelerated paying its suppliers.
Sumitomo Pharma Co Days Payable Related Terms
Sumitomo Pharma Co Days Payable Historical Data
* Premium members only.
The historical data trend for Sumitomo Pharma Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sumitomo Pharma Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Sumitomo Pharma Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sumitomo Pharma Co's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sumitomo Pharma Co (TSE:4506) has a Days Payable of 81.71 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sumitomo Pharma Co and its competitors. This is 50% below median its historical median of 162.50. Over the past decade, Sumitomo Pharma Co's Days Payable has ranged from 78.69 to 175.36. According to the industry distribution chart, Sumitomo Pharma Co ranks #530 out of 922 companies in the Drug Manufacturers industry, placing it in the top 57.5%.
Is Sumitomo Pharma Co's Days Payable too high?
Sumitomo Pharma Co's current Days Payable of 81.71 is 50% below median its 10-year median of 162.50. Over the past 10 years, this metric has ranged from a low of 78.69 to a high of 175.36. The Drug Manufacturers industry median Days Payable is 90.61. Sumitomo Pharma Co's value of 81.71 is 9.8% below this industry median. Based on the distribution chart, Sumitomo Pharma Co ranks #530 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sumitomo Pharma Co has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sumitomo Pharma Co ranks #530 out of 922 companies for Days Payable. This places Sumitomo Pharma Co in the lower half of its industry. The industry median Days Payable is 90.61. Sumitomo Pharma Co's value of 81.71 is 9.8% below this benchmark. Historically, Sumitomo Pharma Co's own Days Payable has ranged from 78.69 to 175.36 over the past decade. While the company's 10-year median is 162.50 vs. the industry median of 90.61, Sumitomo Pharma Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sumitomo Pharma Co's current Days Payable of 81.71 is 9.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sumitomo Pharma Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sumitomo Pharma Co's current Days Payable is 81.71, which is 50% below median its own 10-year median of 162.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (TSE:4506) is currently considered Significantly Overvalued. The stock's GF Value™ is 円832.67, compared to a current price of 円1,525.00 — trading 83.1% above its estimated fair value. The current Days Payable is 81.71, which is 50% below median its 10-year median of 162.50 and 9.8% below the Drug Manufacturers industry median of 90.61. Sumitomo Pharma Co's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sumitomo Pharma Co (TSE:4506), the current Days Payable is 81.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sumitomo Pharma Co (TSE:4506) Overvalued in 2026?
Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued.
The current stock price of 円1,525.00 is trading 83.1% above its estimated GF Value™ of 円832.67.
GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.
Key valuation signals for TSE:4506:
Days Payable: 81.71 (50% below median its 10-year median of 162.50)
GF Value™: 円832.67 vs. price of 円1,525.00 (83.1% above fair value)
Industry Position: 9.8% below the Drug Manufacturers median (#530 of 922)
No single metric tells the full story. See the TSE:4506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
57GF Score
Get the complete analysis for TSE:4506
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4506 has been successfully added to your 
